GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Authors
Keywords
-
Journal
Nature Reviews Nephrology
Volume 13, Issue 10, Pages 605-628
Publisher
Springer Nature
Online
2017-09-04
DOI
10.1038/nrneph.2017.123
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dipeptidyl peptidase-4 activity is associated with urine albumin excretion in type 1 diabetes
- (2017) Lea Duvnjak et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment
- (2017) Lennart Tonneijck et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits
- (2017) Jens Oellgaard et al. KIDNEY INTERNATIONAL
- Kidney disease and obesity: epidemiology, mechanisms and treatment
- (2017) Niels Olsen Saraiva Câmara et al. Nature Reviews Nephrology
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Gastrointestinal–Renal Axis: Role in the Regulation of Blood Pressure
- (2017) Jian Yang et al. Journal of the American Heart Association
- SGLT2 inhibition: a new era in renoprotective medicine?
- (2017) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
- (2017) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- Physiology and pathophysiology of potassium homeostasis
- (2016) Biff F. Palmer et al. ADVANCES IN PHYSIOLOGY EDUCATION
- Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy
- (2016) Ali Asmar et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Exaggerated sympathetic and cardiovascular responses to stimulation of the mesencephalic locomotor region in spontaneously hypertensive rats
- (2016) Nan Liang et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Enteroendocrine Cells: Chemosensors in the Intestinal Epithelium
- (2016) Fiona M. Gribble et al. Annual Review of Physiology
- Linagliptin but not Sitagliptin inhibited transforming growth factor-β2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition
- (2016) Sen Shi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The Cardiovascular Biology of Glucagon-like Peptide-1
- (2016) Daniel J. Drucker Cell Metabolism
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?
- (2016) Karly C. Sourris et al. CURRENT DRUG TARGETS
- Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of diabetic nephropathy in Chinese patients with newly diagnosed type 2 diabetes: A cross-sectional study
- (2016) Tianpeng Zheng et al. Diabetes & Vascular Disease Research
- No Summer Vacation From Diabetes: Glycemic Control in Pediatric Participants in the T1D Exchange Registry Based on Time of Year
- (2016) Jennifer L. Sherr et al. DIABETES CARE
- Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
- (2016) Michael Nauck et al. DIABETES CARE
- Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
- (2016) Jan H. Cornel et al. DIABETES CARE
- Response to Comment on Crews et al. Role and Determinants of Adherence to Off-loading in Diabetic Foot Ulcer Healing: A Prospective Investigation. Diabetes Care 2016;39:1371–1377
- (2016) Ryan T. Crews et al. DIABETES CARE
- Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
- (2016) Ofri Mosenzon et al. DIABETES CARE
- Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
- (2016) Lennart Tonneijck et al. DIABETES CARE
- The effect of liraglutide on renal function: A randomized clinical trial
- (2016) Bernt J. von Scholten et al. DIABETES OBESITY & METABOLISM
- Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men
- (2016) M. H. A. Muskiet et al. DIABETES OBESITY & METABOLISM
- Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial
- (2016) J. Skov et al. DIABETES OBESITY & METABOLISM
- Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas
- (2016) M. M. Smits et al. DIABETES OBESITY & METABOLISM
- Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials
- (2016) Katherine R. Tuttle et al. DIABETES OBESITY & METABOLISM
- Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients
- (2016) Mark M. Smits et al. DIABETES OBESITY & METABOLISM
- Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
- (2016) M. Nauck DIABETES OBESITY & METABOLISM
- Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas
- (2016) C. F. Deacon et al. DIABETES OBESITY & METABOLISM
- Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
- (2016) Lennart Tonneijck et al. DIABETOLOGIA
- Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
- (2016) Mark M. Smits et al. DIABETOLOGIA
- Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial
- (2016) Christian Ott et al. DIABETOLOGIA
- GLP-1 based therapies: clinical implications for gastroenterologists
- (2016) Mark M Smits et al. GUT
- Gastrorenal Axis
- (2016) Pedro A. Jose et al. HYPERTENSION
- Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor AlogliptinNovelty and Significance
- (2016) William B. White et al. HYPERTENSION
- Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials
- (2016) J. Kongwatcharapong et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Evolving Concepts and Translational Relevance of Enteroendocrine Cell Biology
- (2016) Daniel J. Drucker JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes
- (2016) Xiaodan Zhang et al. JOURNAL OF HYPERTENSION
- Stromal cell–derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy
- (2016) Satoru Takashima et al. KIDNEY INTERNATIONAL
- Association Between Use of Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Kidney Injury: A Nested Case-Control Study
- (2016) Chia-Jen Shih et al. MAYO CLINIC PROCEEDINGS
- Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
- (2016) Abd A. Tahrani et al. Nature Reviews Endocrinology
- Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
- (2016) Ralph A. DeFronzo et al. Nature Reviews Nephrology
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
- (2016) Laurent Azoulay et al. BMJ-British Medical Journal
- Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
- (2016) Laurent Azoulay et al. BMJ-British Medical Journal
- GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?
- (2016) Michael A Nauck et al. Lancet Diabetes & Endocrinology
- Renoprotection in LEADER and EMPA-REG OUTCOME
- (2016) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- The changing face of diabetes complications
- (2016) Edward W Gregg et al. Lancet Diabetes & Endocrinology
- Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
- (2016) Juan P Frías et al. Lancet Diabetes & Endocrinology
- The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions
- (2016) Michael A Nauck et al. Lancet Diabetes & Endocrinology
- Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice
- (2016) Gwon-Soo Jung et al. Diabetes & Metabolism Journal
- Kidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes
- (2015) Mark E. Cooper et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men
- (2015) Ali Asmar et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- A new combination of sitagliptin and furosemide protects against remote myocardial injury induced by renal ischemia/reperfusion in rats
- (2015) Mahmoud I. Youssef et al. BIOCHEMICAL PHARMACOLOGY
- Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats
- (2015) Xiaoyan Zhou et al. Cardiovascular Diabetology
- Response to Letter Regarding Article, “Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial”
- (2015) Benjamin M. Scirica et al. CIRCULATION
- Letter by Muskiet et al Regarding Article, “Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial”
- (2015) Marcel H.A. Muskiet et al. CIRCULATION
- Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
- (2015) Feng Sun et al. CLINICAL THERAPEUTICS
- GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study
- (2015) Kristine Færch et al. DIABETES
- Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
- (2015) Juris J. Meier et al. DIABETES CARE
- Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels
- (2015) Mark M. Smits et al. DIABETES CARE
- Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Giulia Ferrannini et al. DIABETES CARE
- Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials
- (2015) A. S. Abbas et al. DIABETES OBESITY & METABOLISM
- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
- (2015) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice
- (2015) Sander Kooijman et al. DIABETOLOGIA
- Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy
- (2015) Eunsoo Jung et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Diabetes
- (2015) David M. Nathan JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial
- (2015) Caroline K. Kramer et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study
- (2015) Manfredi Rizzo et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes
- (2015) Bernt Johan von Scholten et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Deep Sequencing in Microdissected Renal Tubules Identifies Nephron Segment-Specific Transcriptomes
- (2015) J. W. Lee et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition
- (2015) Sen Shi et al. KIDNEY INTERNATIONAL
- Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin
- (2015) Michael Zeisberg et al. KIDNEY INTERNATIONAL
- Incretin-based drugs and renoprotection—is hyperfiltration key?
- (2015) Lennart Tonneijck et al. KIDNEY INTERNATIONAL
- Gut–kidney kaliuretic signaling: looking forward to feeding
- (2015) Ewout J. Hoorn et al. KIDNEY INTERNATIONAL
- Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
- (2015) Merlin C. Thomas et al. Nature Reviews Nephrology
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protective effect of sitagliptin against renal ischemia reperfusion injury in rats
- (2015) Ayse Nuransoy et al. RENAL FAILURE
- A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients
- (2015) K. Esposito et al. BMJ Open
- Pleiotropic effects of type 2 diabetes management strategies on renal risk factors
- (2015) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
- (2015) Sri Harsha Tella et al. Therapeutic Advances in Endocrinology and Metabolism
- Sitagliptin protects rat kidneys from acute ischemia-reperfusion injury via upregulation of GLP-1 and GLP-1 receptors
- (2014) Meng-wei Chang et al. ACTA PHARMACOLOGICA SINICA
- Observational Study of Kidney Function and Albuminuria in Patients With Type 2 Diabetes Treated With Exenatide BID Versus Insulin Glargine
- (2014) Manjiri Pawaskar et al. ANNALS OF PHARMACOTHERAPY
- Blood Pressure-Lowering Effects of Incretin-Based Diabetes Therapies
- (2014) Julie A. Lovshin et al. Canadian Journal of Diabetes
- Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
- (2014) Benjamin M. Scirica et al. CIRCULATION
- Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2014) André J. Scheen CLINICAL PHARMACOKINETICS
- DPP-4 Inhibitors—Renoprotection in Diabetic Nephropathy?
- (2014) Usha Panchapakesan et al. DIABETES
- Pleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors
- (2014) B. Omar et al. DIABETES
- Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
- (2014) Keizo Kanasaki et al. DIABETES
- GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
- (2014) L. van Bloemendaal et al. DIABETES
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes
- (2014) Julie A. Lovshin et al. DIABETES CARE
- Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment
- (2014) P.-H. Groop et al. DIABETES OBESITY & METABOLISM
- Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment
- (2014) B. J. von Scholten et al. DIABETIC MEDICINE
- Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
- (2014) Erin E. Mulvihill et al. ENDOCRINE REVIEWS
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- Elimination and Degradation of Glucagon-like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Patients with End-Stage Renal Disease
- (2014) Thomas Idorn et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Endogenous Glucagon-Like Peptide-1 Reduces Drinking Behavior and Is Differentially Engaged by Water and Food Intakes in Rats
- (2014) Naomi J. McKay et al. JOURNAL OF NEUROSCIENCE
- Liraglutide ameliorates renal injury in streptozotocin-induced diabetic rats by activating endothelial nitric oxide synthase activity via the downregulation of the nuclear factor-κB pathway
- (2014) SAI-JUN ZHOU et al. Molecular Medicine Reports
- Therapeutic approaches to diabetic nephropathy—beyond the RAS
- (2014) Beatriz Fernandez-Fernandez et al. Nature Reviews Nephrology
- Increased plasma dipeptidyl peptidase 4 activities predict new-onset microalbuminuria in association with its proinflammatory effects in Chinese without diabetes: a four-year prospective study
- (2014) T. Zheng et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Changes in Diabetes-Related Complications in the United States, 1990–2010
- (2014) Edward W. Gregg et al. NEW ENGLAND JOURNAL OF MEDICINE
- DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat
- (2014) Ravi Nistala et al. Obesity
- Combining incretin-based drugs and RAAS inhibitors: more cons than pros?
- (2014) Lennart Tonneijck et al. Lancet Diabetes & Endocrinology
- Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison
- (2014) Paul Craddy et al. Diabetes Therapy
- Effects of Exenatide on Kidney Function, Adverse Events, and Clinical End Points of Kidney Disease in Type 2 Diabetes
- (2013) Katherine R. Tuttle et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Glucagon-Like Peptide-1: Glucose Homeostasis and Beyond
- (2013) Young Min Cho et al. Annual Review of Physiology
- Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes
- (2013) Ryo Kodera et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Physiological mechanisms for the increase in renal solute-free water clearance by a glucagon-like peptide-1 mimetic
- (2013) Anna V Kutina et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
- (2013) P.-H. Groop et al. DIABETES CARE
- Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes: Systematic review and meta-analysis of clinical studies
- (2013) S. Calanna et al. DIABETES CARE
- Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes
- (2013) Koji Sakata et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies
- (2013) S. Calanna et al. DIABETOLOGIA
- DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1^|^alpha; in type 2 diabetic patients with incipient nephropathy
- (2013) Hiroki Fujita et al. ENDOCRINE JOURNAL
- Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men
- (2013) Jeppe Skov et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
- (2013) L van Bloemendaal et al. JOURNAL OF ENDOCRINOLOGY
- Glucagon-Like Peptide-1 Receptor Agonist Administration Suppresses Both Water and Saline Intake in Rats
- (2013) N. J. McKay et al. JOURNAL OF NEUROENDOCRINOLOGY
- Exendin-4 ameliorates renal ischemia-reperfusion injury in the rat
- (2013) Hua Yang et al. JOURNAL OF SURGICAL RESEARCH
- Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction
- (2013) Yen-Ta Chen et al. Journal of Translational Medicine
- The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential
- (2013) Hiroki Fujita et al. KIDNEY INTERNATIONAL
- Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
- (2013) Steven E Kahn et al. LANCET
- GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure
- (2013) Minsuk Kim et al. NATURE MEDICINE
- The gut as a sensory organ
- (2013) John B. Furness et al. Nature Reviews Gastroenterology & Hepatology
- The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
- (2013) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
- (2013) Linda F. Fried et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Achievement of Goals in U.S. Diabetes Care, 1999–2010
- (2013) Mohammed K. Ali et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Glucagon-Like Peptide-1 Receptor Agonist, Liraglutide, Attenuates the Progression of Overt Diabetic Nephropathy in Type 2 Diabetic Patients
- (2013) Shigeki Imamura et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus
- (2013) Hiroko Mori et al. Journal of Diabetes Investigation
- Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males
- (2013) Jeppe Skov et al. Endocrine Connections
- DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis
- (2012) Matteo Monami et al. ADVANCES IN THERAPY
- Glucagon-Like Peptide-1 Receptor Agonist Inhibits Asymmetric Dimethylarginine Generation in the Kidney of Streptozotocin-Induced Diabetic Rats by Blocking Advanced Glycation End Product–Induced Protein Arginine Methyltranferase-1 Expression
- (2012) Ayako Ojima et al. AMERICAN JOURNAL OF PATHOLOGY
- Inhibition of the Expression of TGF-�1 and CTGF in Human Mesangial Cells byExendin-4, a Glucagon-like Peptide-1Receptor Agonist
- (2012) Wenbin Li et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKC Activation in Diabetes
- (2012) A. Mima et al. DIABETES
- Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease
- (2012) Ai-li Sun et al. Diabetes & Vascular Disease Research
- Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
- (2012) J. C. Arjona Ferreira et al. DIABETES CARE
- Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study
- (2012) J. B. McGill et al. DIABETES CARE
- Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis
- (2012) M. Pendergrass et al. DIABETES OBESITY & METABOLISM
- Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis
- (2012) S.-C. Liu et al. DIABETES OBESITY & METABOLISM
- Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight
- (2012) J. Jelsing et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl Peptidase IV Regulates Proliferation of Preglomerular Vascular Smooth Muscle and Mesangial Cells
- (2012) Edwin K. Jackson et al. HYPERTENSION
- DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy
- (2012) Markus L. Alter et al. KIDNEY & BLOOD PRESSURE RESEARCH
- Exenatide Reduces Urinary Transforming Growth Factor-ß1 and Type IV Collagen Excretion in Patients with Type 2 Diabetes and Microalbuminuria
- (2012) Hong Zhang et al. KIDNEY & BLOOD PRESSURE RESEARCH
- Sodium challenge does not support an acute gastrointestinal–renal natriuretic signaling axis in humans
- (2012) Richard A. Preston et al. KIDNEY INTERNATIONAL
- GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases
- (2012) Hari Hendarto et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A
- (2012) Yuji Ishibashi et al. MICROVASCULAR RESEARCH
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Attenuation of Renovascular Damage in Zucker Diabetic Fatty Rat by NWT-03, an Egg Protein Hydrolysate with ACE- and DPP4-Inhibitory Activity
- (2012) Yumei Wang et al. PLoS One
- Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects
- (2012) Jutta Keller et al. REGULATORY PEPTIDES
- Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake
- (2011) Naomi J. McKay et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes
- (2011) R. Kodera et al. DIABETOLOGIA
- Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes
- (2011) Jonatan I. Bagger et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Glucagon-like peptide–1 suppresses advanced glycation end product–induced monocyte chemoattractant protein–1 expression in mesangial cells by reducing advanced glycation end product receptor level
- (2011) Yuji Ishibashi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure
- (2010) Mads Halbirk et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition
- (2010) M. C. Bunck et al. DIABETES CARE
- The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1
- (2010) G. P. Fadini et al. DIABETES CARE
- Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
- (2010) C. F. Deacon DIABETES OBESITY & METABOLISM
- Exenatide Versus Glibenclamide in Patients with Diabetes
- (2010) G. Derosa et al. Diabetes Technology & Therapeutics
- Sitagliptin reduces albuminuria in patients with type 2 diabetes [Rapid Communication]
- (2010) Sachiko Hattori ENDOCRINE JOURNAL
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Role of dipeptidyl peptidase IV (DPP4) in the development of dyslipidemia: DPP4 contributes to the steroid metabolism pathway
- (2010) Youichi Sato et al. LIFE SCIENCES
- Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes
- (2010) Jitendra Vaghasiya et al. REGULATORY PEPTIDES
- Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP
- (2009) Rolf Mentlein BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside
- (2009) Marc Vanderheyden et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue
- (2009) J. Jendle et al. DIABETES OBESITY & METABOLISM
- Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus
- (2009) K. Aaboe et al. DIABETES OBESITY & METABOLISM
- Mouse Models of Diabetic Nephropathy
- (2009) F. C. Brosius et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas
- (2008) J. de Heer et al. DIABETOLOGIA
- Regulation of Islet Hormone Release and Gastric Emptying by Endogenous Glucagon-Like Peptide 1 after Glucose Ingestion
- (2008) Marzieh Salehi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats
- (2008) Yasushi Kirino et al. JOURNAL OF ENDOCRINOLOGY
- Control of Renal Solute Excretion by Enteric Signals and Mediators
- (2008) L. Thomas et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
- Diagnostic Value of the Aminopeptidase N, N-Acetyl-β-D-Glucosaminidase and Dipeptidylpeptidase IV in Evaluating Tubular Dysfunction in Patients with Glomerulopathies
- (2008) Branka Mitic et al. RENAL FAILURE
- Regulation of Renal Function by the Gastrointestinal Tract: Potential Role of Gut-Derived Peptides and Hormones
- (2007) A.R. Michell et al. Annual Review of Physiology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started